Literature DB >> 1407572

National General Practice Study of Epilepsy (NGPSE): partial seizure patterns in a general population.

M Manford1, Y M Hart, J W Sander, S D Shorvon.   

Abstract

The National General Practice Study of Epilepsy (NGPSE) is a prospective community-based study of newly diagnosed epileptic seizures. Of 594 patients with definite epileptic seizures, 160 (26.9%) had seizures with a clinically localizable onset: 36 (22.5%) frontal, 52 (32.5%) central sensorimotor, 43 (27%) temporal, nine (5.6%) frontotemporal, and 10 each (6.3%) parietal and other posterior cortex. There was no difference among these groups in seizure frequency or remission rate; 46.5% were seizure free and 6.9% had severe epilepsy. Etiology was identifiable in 41% and focal CT and EEG abnormalities in 33% and 19%, with results discordant with the clinical seizure localization in 21% and 20%. Temporal lobe epilepsy may be underreported, as it may be more difficult to localize clinically. Extratemporal seizures are extremely common in the general population, especially frontal and central sensorimotor, in relation to cerebrovascular disease. Prognoses are similar for partial epilepsies with different clinical patterns and regions of onset and are much better than suggested in hospital-based studies. The clinical, EEG, and CT localizations may frequently be discordant in this nonrefractory group.

Entities:  

Mesh:

Year:  1992        PMID: 1407572     DOI: 10.1212/wnl.42.10.1911

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

1.  Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus.

Authors:  J M Parent; T W Yu; R T Leibowitz; D H Geschwind; R S Sloviter; D H Lowenstein
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

2.  Automated volumetry of hippocampus is useful to confirm unilateral mesial temporal sclerosis in patients with radiologically positive findings.

Authors:  Guilherme Silva; Cristina Martins; Nádia Moreira da Silva; Duarte Vieira; Dias Costa; Ricardo Rego; José Fonseca; João Paulo Silva Cunha
Journal:  Neuroradiol J       Date:  2017-06-20

3.  Epilepsy care: a need for change.

Authors:  M P Taylor
Journal:  Br J Gen Pract       Date:  1994-09       Impact factor: 5.386

4.  Neural stem cell grafting in an animal model of chronic temporal lobe epilepsy.

Authors:  Bharathi Hattiangady; Ashok K Shetty
Journal:  Curr Protoc Stem Cell Biol       Date:  2011-09

5.  Mesial Temporal Sclerosis: Accuracy of NeuroQuant versus Neuroradiologist.

Authors:  M Azab; M Carone; S H Ying; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-23       Impact factor: 3.825

6.  Combined effect between two functional polymorphisms of SLC6A12 gene is associated with temporal lobe epilepsy.

Authors:  Jingyun Li; Hua Lin; Fenghe Niu; Xilin Zhu; Ning Shen; Xin Wang; Liping Li; Aihua Liu; Xiaopan Wu; Wei Sun; Yuping Wang; Ying Liu
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

Review 7.  Benign mesial temporal lobe epilepsy.

Authors:  Angelo Labate; Antonio Gambardella; Eva Andermann; Umberto Aguglia; Fernando Cendes; Samuel F Berkovic; Frederick Andermann
Journal:  Nat Rev Neurol       Date:  2011-01-25       Impact factor: 42.937

Review 8.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

9.  Neuropsychological profile of adult patients with nonsymptomatic occipital lobe epilepsies.

Authors:  Leonilda Bilo; Gabriella Santangelo; Ilaria Improta; Carmine Vitale; Roberta Meo; Luigi Trojano
Journal:  J Neurol       Date:  2012-08-18       Impact factor: 4.849

10.  Grafting of striatal precursor cells into hippocampus shortly after status epilepticus restrains chronic temporal lobe epilepsy.

Authors:  Bharathi Hattiangady; Muddanna S Rao; Ashok K Shetty
Journal:  Exp Neurol       Date:  2008-05-15       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.